呼吸器感染症におけるBAY o 9867 (Ciprofloxacin) の検討 CLINICAL STUDIES ON BAY o 9867 (Ciprofloxacin) IN THE RESPIRATORY INFECTIONS

Access this Article

Author(s)

Abstract

新しいキノリンカルボン酸系の合成抗菌剤BAY o 9867を呼吸器感染症39名 (男16名, 女23名, 28~83才, 平均56才) に1回200~400mg, 1日2~3回経口投与し, その臨床効果および副作用を検討した。疾患の内訳は, 肺炎3例, 下気道感染症36例であった。臨床効果は, 著効1例, 有効18例, やや有効11例, 無効8例, 不明1例で有効率50%であった。<BR>臨床効果判定可能な38例中, 緑膿菌下気道感染症が20例 (複数菌検出例2例を含む) で, 内服剤としての効果はかなりの成績と言える。細菌学的効果は, <I>P.aeruginosa</I> 21株中, 菌消失3株, 減少6株, 不変9株, 不明3株で除菌率16.7%であり, <I>H.influenzae</I> 10株は, 菌消失7株, 減少1株, 不変2株で除菌率70%であった。<BR>副作用は, 食欲低下1例認めたが投与中止で軽快した。下痢, 胃障害各1例認めたが継続投与可能であった。血液・生化学検査では, 軽度の好酸球増多, LDH上昇を各1例認めた以外には異常を認めなかった。

Clinical effects and adverse effects of BAY o 9867, a new quinoline-carboxylic acid derivative, were studied in 39 patients with respiratory infections receiving orally 200 mg to 400 mg b.i.d.or t.i.d.Among them, 36 cases were lower respiratory tract infections and 3 cases were pneumonia.<BR>Clinical effects were excellent in 1 case, good in 18 cases, fair in 11 cases, poor in 8 cases and 1 case was not evaluated because of administration of another antibiotics.The efficacy rate was 50%.<BR>As for causative organism, the results were as follows: 21 strains of <I>P.aeruginosa</I> were eradicated in 3 strains, decreased in 6 strains, persisted in 9 strains and unknown in 3 strains, and likewise, 10 strains of <I>H.influenzae</I> were eradicated in 7 strains, decreased in 1 strain, persisted in 2 strains.<BR>As for adverse effects, appetite loss, diarrhea and gastric disorder were observed in each 1 case.Laboratory findings revealed each 1 case with a slight increase in the number of eosinophil and in LDH.

Journal

  • CHEMOTHERAPY

    CHEMOTHERAPY 33(Supplement7), 294-304, 1985

    Japanese Society of Chemotherapy

Codes

Page Top